Preliminary bioavailability study on protacine: a new, non-steroidal anti-inflammatory agent.
Time versus concentration curves of unchanged protacine were measured in the blood of 5 healthy volunteers by high pressure liquid chromatography after a single oral dose of 4 capsules (600 mg). These curves showed a maximum at 8 hours after administration, with an absorption half-life of 3.4 hours, and were interpreted according to the two-compartment open model with invasion. The elimination half-life was found to be 10 hours. This may allow a maintenance treatment, where necessary, with 1 capsule (150 mg) of protacine twice daily and strongly suggests that, apart from acute cases, protacine would be particularly well suited for long-term treatment.
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000097:blood / Q000378:metabolism*; D001682:Biological Availability; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D013997:Time Factors
D000893:Anti-Inflammatory Agents